◆ NeutralCGC
Canopy Growth's Medical Marijuana Sales Are Soaring. Is the Beaten-Down Stock Ready to Rebound?
The Motley Fool·
Canopy Growth reported strong 27% growth in its medical marijuana division in Q4 fiscal 2026, but the rest of the business showed weakness. The recreational marijuana segment grew only 1% in Q4, international cannabis sales fell 7% year-over-year, and the Storz & Bickel vaporizer business declined 14%. The company continues to report negative earnings and faces declining gross margins, making it a risky investment despite one strong division.
Read Full Article at The Motley Fool →